THE WOODLANDS, Texas--(BUSINESS WIRE)--In compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), which requires any NASDAQ listed issuer that receives an audit opinion that contains a “going concern” qualification to make a public announcement to that effect through the news media, Repros Therapeutics Inc. (NasdaqGM:RPRX) reported today that its Annual Report on Form 10-K for the year ended December 31, 2007, included an audit opinion with a going concern qualification.
